We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+25.16%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.69%
AUM
$1.46B
AUM Growth
+$147M
Cap. Flow
-$82.7M
Cap. Flow %
-5.66%
Top 10 Hldgs %
25.13%
Holding
215
New
28
Increased
57
Reduced
41
Closed
25

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$31.1M
2
MRK icon
Merck
MRK
+$27.8M
3
MIRM icon
Mirum Pharmaceuticals
MIRM
+$24.3M
4
IMGN
Immunogen Inc
IMGN
+$14.5M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$14.1M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$29.3M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$28.4M
3
UTHR icon
United Therapeutics
UTHR
+$26.8M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$25.8M
5
PODD icon
Insulet
PODD
+$23.6M

Sector Composition

Rank Sector Weight
1 Healthcare 53.92%
2 Technology 13.34%
3 Industrials 8.74%
4 Consumer Discretionary 4.85%
5 Energy 4.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
1
Krystal Biotech
KRYS
$9.21B
$44M 3.01%
374,951
+233
+0.1% +$23.8K
LEGN icon
2
Legend Biotech
LEGN
$3.68B
$40.9M 2.8%
593,167
-22,166
-4% -$1.45M
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$37.8M 2.58%
414,419
+77,468
+23% +$6.68M
INSP icon
4
Inspire Medical Systems
INSP
$1.5B
$37.4M 2.56%
115,187
-3,671
-3% -$1.05M
ARGX icon
5
argenx
ARGX
$52B
$37.2M 2.54%
95,414
-23,211
-20% -$9.13M
ESTA icon
6
Establishment Labs
ESTA
$2.73B
$36.8M 2.51%
536,015
+79,531
+17% +$5.49M
KDNY
7
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$35.7M 2.44%
928,637
-43,554
-4% -$1.12M
KRTX
8
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$33.8M 2.31%
155,930
+108
+0.1% +$23.1K
SWAV
9
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$32.3M 2.21%
112,999
+92
+0.1% +$25.5K
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$31.6M 2.16%
+499,503
New +$31.1M
TMDX icon
11
Transmedics
TMDX
$2.82B
$30.9M 2.11%
367,631
+223
+0.1% +$17.1K
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.02B
$30.5M 2.08%
791,118
+354,403
+81% +$14.1M
AXSM icon
13
Axsome Therapeutics
AXSM
$10.9B
$28.4M 1.94%
394,884
+54,454
+16% +$4.02M
MRK icon
14
Merck
MRK
$316B
$28.3M 1.93%
+244,934
New +$27.8M
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$119B
$28.2M 1.93%
80,116
-10,175
-11% -$3.43M
DAWN
16
DELISTED
Day One Biopharmaceuticals
DAWN
$26.7M 1.83%
2,237,111
+633,721
+40% +$8.28M
VRNA
17
DELISTED
Verona Pharma
VRNA
$24.6M 1.68%
1,163,355
+222,055
+24% +$4.74M
MIRM icon
18
Mirum Pharmaceuticals
MIRM
$6.38B
$23.7M 1.62%
+915,119
New +$24.3M
IMGN
19
DELISTED
Immunogen Inc
IMGN
$23.1M 1.58%
+1,224,127
New +$14.5M
PCVX icon
20
Vaxcyte
PCVX
$7.73B
$23M 1.57%
460,164
+26,364
+6% +$1.25M
ROIV icon
21
Roivant Sciences
ROIV
$24.1B
$22.8M 1.56%
2,265,323
+1,192,940
+111% +$10.7M
LNTH icon
22
Lantheus
LNTH
$6.59B
$22.6M 1.55%
269,769
-108,336
-29% -$9.72M
CYTK icon
23
Cytokinetics
CYTK
$10.4B
$22.3M 1.52%
682,867
+71,877
+12% +$2.66M
MPWR icon
24
Monolithic Power Systems
MPWR
$66B
$19.5M 1.33%
36,047
-3,796
-10% -$1.8M
DICE
25
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$19.3M 1.32%
416,151
– –
1
2 3 4 5

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Nicholas Investment Partners held 215 positions worth $1.46B, up 11% from $1.32B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Nicholas Investment Partners withdrew a net $82.7M in Q2 2023, closing 25 positions and reducing 41 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $29.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 53% a quarter earlier, followed by Technology and Industrials.

Against the trend, Nicholas Investment Partners opened a new position in Intra-Cellular Therapies Inc. worth $31.6M.

  • Nicholas Investment Partners's largest Q2 2023 buy was Intra-Cellular Therapies Inc.: 499,503 shares worth $31.6M.
  • Nicholas Investment Partners added most to Xenon Pharmaceuticals in Q2 2023, an estimated $14.1M increase.
  • Nicholas Investment Partners's biggest Q2 2023 reduction was Lantheus, cutting an estimated $9.72M.
  • Nicholas Investment Partners fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $29.3M.
  • Nicholas Investment Partners's ten largest holdings make up 25% of its $1.46B portfolio in Q2 2023.
  • Nicholas Investment Partners opened 28 new positions and closed 25 in Q2 2023.
  • Nicholas Investment Partners's portfolio value rose 11% quarter-over-quarter to $1.46B.

Based on Nicholas Investment Partners's 13F filing for Q2 2023, filed 10 Aug 2023.